Cytokinetics, Incorporated

It out-grows 79% of companies worldwide.

Revenue is set to grow 113%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 113%/yr from here.

The runway holds up: revenue is set to grow 90%/yr over five years.10/10

None flagged.

Revenue fell 2%/yr over the last 3 years, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

Strong long-term results. Long-term holders have seen +100% over three years and +61% over five, ahead of 60% of the market.

It's up 0.5% over the past year, but 31% below its 52-week high. That is a touch behind the market.

Returns sit at the market level so far this year (-4%).

The stock is underperforming over the past month (-19%) and over three months (-28%).

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the stock is underperforming over the past month and over three months.